Pfizer: Cancer drug narrowly misses study goal

Pfizer Inc.’s advanced kidney cancer treatment Inlyta missed its main late-stage study goal when compared to another drug in patients who had not been treated for the disease. The New York drugmaker said Wednesday that patients taking Inlyta had a median progression-free survival that exceeded that …